TY - JOUR
T1 - SOHO State of the Art Update and Next Questions
T2 - Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
AU - Short, Nicholas J.
AU - Kantarjian, Hagop
AU - Pui, Ching Hon
AU - Goldstone, Anthony
AU - Jabbour, Elias
N1 - Funding Information:
Supported by the M.D. Anderson Cancer Center Support Grant CA016672.
Publisher Copyright:
© 2018 Elsevier Inc.
PY - 2018/7
Y1 - 2018/7
N2 - The widespread adoption of Bcr–Abl-directed tyrosine kinase inhibitors (TKIs) into first-line regimens for patients with Philadelphia chromosome (Ph)-positive (Ph + ) acute lymphoblastic leukemia (ALL) has revolutionized the outcomes of patients with this disease. Whereas Ph + ALL was historically associated with cure rates of <25% in the pre-TKI era, now long-term survival in more than 75% of patients has been reported. With the promising efficacy of later-generation TKIs (eg, ponatinib) and the emerging understanding of the prognostic significance of various cooperative genomic alterations and of minimal residual disease, the widespread use of allogeneic hematopoietic stem cell transplantation in first remission for patients with Ph + ALL has been increasingly questioned. Furthermore, with the development of more potent Bcr-Abl TKIs, several studies are evaluating novel strategies that reduce or eliminate chemotherapy. Herein, we review the major genomic and molecular prognostic factors in Ph + ALL and also discuss the current and future treatment paradigms for this disease.
AB - The widespread adoption of Bcr–Abl-directed tyrosine kinase inhibitors (TKIs) into first-line regimens for patients with Philadelphia chromosome (Ph)-positive (Ph + ) acute lymphoblastic leukemia (ALL) has revolutionized the outcomes of patients with this disease. Whereas Ph + ALL was historically associated with cure rates of <25% in the pre-TKI era, now long-term survival in more than 75% of patients has been reported. With the promising efficacy of later-generation TKIs (eg, ponatinib) and the emerging understanding of the prognostic significance of various cooperative genomic alterations and of minimal residual disease, the widespread use of allogeneic hematopoietic stem cell transplantation in first remission for patients with Ph + ALL has been increasingly questioned. Furthermore, with the development of more potent Bcr-Abl TKIs, several studies are evaluating novel strategies that reduce or eliminate chemotherapy. Herein, we review the major genomic and molecular prognostic factors in Ph + ALL and also discuss the current and future treatment paradigms for this disease.
KW - Acute lymphoblastic leukemia
KW - Minimal residual disease
KW - Philadelphia chromosome
KW - Prognostic factors
KW - Tyrosine kinase inhibitor
UR - http://www.scopus.com/inward/record.url?scp=85047495522&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85047495522&partnerID=8YFLogxK
U2 - 10.1016/j.clml.2018.05.015
DO - 10.1016/j.clml.2018.05.015
M3 - Review article
C2 - 29853276
AN - SCOPUS:85047495522
SN - 2152-2650
VL - 18
SP - 439
EP - 446
JO - Clinical Lymphoma, Myeloma and Leukemia
JF - Clinical Lymphoma, Myeloma and Leukemia
IS - 7
ER -